ACA
ALXN

Atlas Capital Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Atlas Capital Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-439
Closed -$80.6K – 978
2021
Q2 		$80.6K Buy
439
+185
+73% +$31.8K 0.01% 474
2021
Q1 		$38.8K Buy
+254
New +$39.3K 0.01% 522
2020
Q2 		– Sell
-189
Closed -$17K – 750
2020
Q1 		$17K Sell
189
-66
-26% -$6.48K 0.01% 540
2019
Q4 		$27.6K Buy
+255
New +$27.3K 0.01% 512

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Atlas Capital Advisors's ALXN Position: Q3 2021 in Review

Atlas Capital Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 439 shares — an estimated $80.6K sold.

Atlas Capital Advisors first reported a position in ALXN in Q4 2019 and held it in 4 quarters. The position peaked at $80.6K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Atlas Capital Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Atlas Capital Advisors sold 439 Alexion Pharmaceuticals shares in Q3 2021, an estimated $80.6K.
  • Atlas Capital Advisors first reported a position in Alexion Pharmaceuticals in Q4 2019 and held it in 4 quarters.
  • Atlas Capital Advisors's Alexion Pharmaceuticals position peaked at $80.6K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Atlas Capital Advisors's 13F filing for Q3 2021, filed 28 Oct 2021.